FDA Warning Letter To SkinPrint Cites GMP Violations, Unapproved New Acne Drug
Executive Summary
The Skin Atelier, Inc., dba Skinprint, appears to have discontinued sales of OTC drug products on its website, along with Spot-On With 5% Micro-Benz Benzoyl Peroxide Spot Treatment, an unapproved new drug product that the FDA cited in a 1 October warning letter amid a host of GMP violations.
You may also be interested in...
Innovating Outside OTC Monograph Lines: Trending Acne Patches, Hand And Foot Antiperspirants
Industry and the FDA agree that the OTC drug monograph system is direly in need of reform, but innovating with noncompliant dosage forms and indications, without approved new drug applications, is a risk companies need to weigh seriously, says Arnall Golden Gregory partner Alan Minsk. The FDA offers perspective on its OTC monographs for acne and antiperspirant products.
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.
L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts
Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.